

Artur Jurczyszyn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2296997/publications.pdf>

Version: 2024-02-01

141
papers

3,747
citations

236925

25
h-index

144013

57
g-index

164
all docs

164
docs citations

164
times ranked

4521
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
2	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 2096-2107.	13.7	435
3	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-664.	1.6	330
4	International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease. <i>Journal of Clinical Oncology</i> , 2013, 31, 2347-2357.	1.6	307
5	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 1563-1573.	13.7	188
6	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
7	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2019, 133, 1953-1963.	1.4	94
8	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	4.1	83
9	HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. <i>Journal of Hematology and Oncology</i> , 2021, 14, 54.	17.0	75
10	Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications. <i>World Journal of Gastroenterology</i> , 2016, 22, 1067.	3.3	69
11	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67
12	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	6.2	57
13	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	4.1	47
14	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	4.1	45
15	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	2.5	41
16	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. <i>Hematological Oncology</i> , 2013, 31, 41-48.	1.7	39
17	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539.	12.8	38
18	n-3 Fatty acids as resolvents of inflammation in the A549 cells. <i>Pharmacological Reports</i> , 2015, 67, 610-615.	3.3	35

#	ARTICLE	IF	CITATIONS
19	Plasma fatty acid profile in multiple myeloma patients. <i>Leukemia Research</i> , 2015, 39, 400-405.	0.8	35
20	Erythrocyte membrane fatty acids in multiple myeloma patients. <i>Leukemia Research</i> , 2014, 38, 1260-1265.	0.8	33
21	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. <i>Leukemia</i> , 2019, 33, 2324-2330.	7.2	33
22	CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. <i>Molecular Cancer</i> , 2021, 20, 84.	19.2	33
23	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. <i>International Journal of Cancer</i> , 2015, 136, E351-8.	5.1	30
24	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	1.3	30
25	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.	3.7	28
26	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2021, 106, 1182-1187.	3.5	27
27	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <i>Kidney International</i> , 2020, 98, 1108-1119.	5.2	26
28	Hematogenous extramedullary relapse in multiple myeloma – a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019, 94, 1132-1140.	4.1	24
29	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	1.3	23
30	Mortality Following <i>Clostridioides difficile</i> Infection in Europe: A Retrospective Multicenter Case-Control Study. <i>Antibiotics</i> , 2021, 10, 299.	3.7	23
31	Characteristics and outcomes of patients with multiple myeloma aged 21–40 years versus 41–60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	2.5	21
32	HGF, sIL-6R and TGF- β 1 Play a Significant Role in the Progression of Multiple Myeloma. <i>Journal of Cancer</i> , 2014, 5, 518-524.	2.5	17
33	Bortezomib for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 173-185.	2.2	17
34	Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2020, 10, 767.	2.8	16
35	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048.	1.8	16
36	Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor. <i>Journal of Cancer</i> , 2014, 5, 480-490.	2.5	15

#	ARTICLE	IF	CITATIONS
37	Whole-Body Low-Dose Computed Tomography (WBLDCT) in Assessment of Patients with Multiple Myeloma – Pilot Study and Standard Imaging Protocol Suggestion. <i>Polski Przegląd Radiologii i Medycyny Nuklearnej</i> , 2017, 82, 356-363.	1.0	15
38	Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. <i>Toxicology Letters</i> , 2015, 236, 75-81.	0.8	14
39	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations – An Extensive Replication of the Associations from the Candidate Gene Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 670-674.	2.5	13
40	The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a “real-world” study: Polish Myeloma Group experience. <i>European Journal of Haematology</i> , 2018, 101, 354-361.	2.2	13
41	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. <i>Leukemia and Lymphoma</i> , 2019, 60, 471-476.	1.3	13
42	Suppression of steroid 5 α -reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. <i>Cell Death and Disease</i> , 2021, 12, 206.	6.3	13
43	The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment. <i>Journal of Cancer</i> , 2015, 6, 160-168.	2.5	12
44	Multiple Myeloma in Pregnancy – A Review of the Literature and a Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e39-e45.	0.4	12
45	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. <i>Leukemia and Lymphoma</i> , 2017, 58, 2089-2100.	1.3	12
46	New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 1828.	2.4	12
47	Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	4.1	12
48	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. <i>Endocrine-Related Cancer</i> , 2015, 22, 545-559.	3.1	11
49	Autologous peripheral blood stem cell transplantation in dialysis-dependent multiple myeloma patients – DAUTOS Study of the Polish Myeloma Study Group. <i>European Journal of Haematology</i> , 2018, 101, 475-485.	2.2	11
50	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 183, 375-384.	2.5	11
51	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1803-1811.	1.3	11
52	Modified Pulsatillae decoction inhibits DSS-induced ulcerative colitis in vitro and in vivo via IL-6/STAT3 pathway. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 179.	2.7	11
53	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	4.1	11
54	Percutaneous Vertebroplasty for Pathological Vertebral Compression Fractures Secondary to Multiple Myeloma – Medium-Term and Long-Term Assessment of Pain Relief and Quality of Life. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 651-656.	1.4	11

#	ARTICLE	IF	CITATIONS
55	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.4	11
56	The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2015, 94, 109-114.	2.2	10
57	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytowych na rok 2016. <i>Acta Haematologica Polonica</i> , 2016, 47, 39-85.	0.3	10
58	The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1440-1452.	0.7	10
59	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74.	6.2	10
60	Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4666.	3.7	10
61	18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. <i>Wspolczesna Onkologia</i> , 2019, 23, 23-31.	1.4	9
62	New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1652.	2.4	9
63	A fatal case of acquired hemophagocytic lymphohistiocytosis (macrophage activation syndrome) in the initial course of dermatomyositis with anti-IL-1 antibody. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 2171-2174.	1.9	8
64	Identification of miRSNPs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017, 140, 526-534.	5.1	8
65	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. <i>Kidney International</i> , 2020, 98, 1407-1418.	5.2	8
66	Leukaemia cutis for clinicians, a literature review. <i>Postepy Dermatologii I Alergologii</i> , 2021, 38, 359-365.	0.9	8
67	Resolvin D1 down-regulates CYP1A1 and PTGS2 gene in the HUVEC cells treated with benzo(a)pyrene. <i>Pharmacological Reports</i> , 2016, 68, 939-944.	3.3	7
68	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. <i>Annals of Hematology</i> , 2017, 96, 1693-1698.	1.8	7
69	Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma - Polish retrospective multicenter analysis. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 765-774.	0.4	7
70	The relationship between plasma renin activity and serum lipid profiles in patients with primary arterial hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2018, 19, 147032031881002.	1.7	6
71	Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. <i>American Journal of Hematology</i> , 2018, 93, E238-E241.	4.1	6
72	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	1.4	6
74	Current status and achievements of Polish haemato-oncology. <i>Acta Haematologica Polonica</i> , 2021, 52, 4-17.	0.3	6
75	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. <i>Acta Haematologica Polonica</i> , 2012, 43, 7-47.	0.3	5
76	Transient cortical blindness after coronary artery angiography. <i>Postepy W Kardiologii Interwencyjnej</i> , 2013, 1, 105-108.	0.2	5
77	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2017. <i>Acta Haematologica Polonica</i> , 2017, 48, 55-103.	0.3	5
78	Interaction between functional polymorphisms in FCER1A and TLR2 and the severity of atopic dermatitis. <i>Human Immunology</i> , 2020, 81, 709-713.	2.4	5
79	Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma. <i>Blood</i> , 2019, 134, 782-782.	1.4	5
80	Plasma Cell Leukemia â€œ Facts and Controversies: More Questions than Answers?. <i>Clinical Hematology International</i> , 2020, 2, 133.	1.7	5
81	Non-secretory multiple myeloma: Diagnosis and management. <i>Advances in Clinical and Experimental Medicine</i> , 2021, 31, 95-100.	1.4	5
82	A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479.	2.8	5
83	Clinical implications of cytogenetic and molecular aberrations in multiple myeloma. <i>Acta Haematologica Polonica</i> , 2021, 52, 18-28.	0.3	5
84	Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effectiveâ€”A report by Polish Myeloma Study Group. <i>Leukemia Research</i> , 2014, 38, 788-794.	0.8	4
85	High expression of CC chemokine receptor 5 (CCR5) promotes disease progression in patients with B-cell non-Hodgkin lymphomas. <i>Current Problems in Cancer</i> , 2018, 42, 268-275.	2.0	4
86	Fatty acids and selected endocannabinoids content in cerebrospinal fluids from patients with neuroinfections. <i>Metabolic Brain Disease</i> , 2019, 34, 331-339.	2.9	4
87	Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma. <i>Mediators of Inflammation</i> , 2020, 2020, 1-13.	3.0	4
88	Risk factors and causes for early mortality in patients with newly diagnosed multiple myeloma in a "real world" study: experiences of the Polish Myeloma Group. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 527-534.	0.4	4
89	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2018/2019. <i>Acta Haematologica Polonica</i> , 2018, 49, 157-206.	0.3	4
90	Abnormal hemostasis screening tests leading to diagnosis of multiple myeloma. <i>Acta Haematologica Polonica</i> , 2019, 50, 32-35.	0.3	4

#	ARTICLE	IF	CITATIONS
91	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. <i>Oncology Letters</i> , 2019, 18, 5811-5820.	1.8	4
92	Rheological properties of erythrocytes in patients infected with <i>Clostridium difficile</i> . <i>Postepy Higieny i Medycyny Doswiadczałnej</i> , 2014, 68, 1397-1405.	0.1	4
93	Transgelin-2 in Multiple Myeloma: A New Marker of Renal Impairment?. <i>Molecules</i> , 2022, 27, 79.	3.8	4
94	Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group. <i>Journal of Clinical Apheresis</i> , 2018, 33, 249-258.	1.3	3
95	Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma – Polish Lymphoma Research Group real-life analysis. <i>Pharmacological Reports</i> , 2019, 71, 473-477.	3.3	3
96	Cereblon (<i>CRBN</i>) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. <i>Leukemia and Lymphoma</i> , 2020, 61, 699-706.	1.3	3
97	Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant. <i>Transplantation Proceedings</i> , 2020, 52, 2186-2192.	0.6	3
98	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	1.3	3
99	Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival. <i>International Journal of Cancer</i> , 2021, 148, 1887-1894.	5.1	3
100	Amyloidosis, extramedullary plasmacytoma and light chain disease: impressive results of daratumumab therapy. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 297-298.	0.4	3
101	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021, 149, 327-336.	5.1	3
102	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	1.4	3
103	Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. <i>Blood</i> , 2019, 134, 1893-1893.	1.4	3
104	Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes. <i>Leukemia and Lymphoma</i> , 2022, 63, 984-990.	1.3	3
105	Therapeutic role of eicosapentaenoic and arachidonic acid in benzo(a) pyrene-induced toxicity in HUVEC endothelial cells. <i>Life Sciences</i> , 2022, 293, 120345.	4.3	3
106	The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment. <i>Medicina (Lithuania)</i> , 2022, 58, 417.	2.0	3
107	ZajÄ™mie oÅrodkowego ukÅadu nerwowego w przebiegu szpiczaka plazmocytoewego – opis przypadku i przeglÄd literatury. <i>Acta Haematologica Polonica</i> , 2015, 46, 242-247.	0.3	2
108	Intraoral manifestation of systemic AL amyloidosis with unique microscopic presentation of intracellular amyloid deposition in striated muscles. <i>Polish Journal of Pathology</i> , 2018, 69, 200-204.	0.3	2

#	ARTICLE	IF	CITATIONS
109	Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group. <i>Advances in Medical Sciences</i> , 2020, 65, 429-436.	2.1	2
110	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. <i>Haematologica</i> , 2021, 106, 601-604.	3.5	2
111	The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs. <i>Blood</i> , 2019, 134, 1899-1899.	1.4	2
112	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2022, 107, 774-775.	3.5	2
113	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	2.5	2
114	Monoklonalne przeciwciaÅa w szpiczaku plazmocytowym – przeÅom w terapii. <i>Acta Haematologica Polonica</i> , 2015, 46, 359-367.	0.3	1
115	<i>Clostridium difficile</i> caused changes in fatty acids profile and resolvin D1 content in plasma of infected patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 318-324.	1.6	1
116	Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group. <i>Archives of Medical Science</i> , 2020, , .	0.9	1
117	Erythropoietin: a story of a discovery with Polish contribution. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 317-319.	0.4	1
118	Blocking MET receptor signaling in multiple myeloma cells in vitro and in vivo. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 153-158.	1.4	1
119	Elements of Immunoglobulin E Network Associate with Aortic Valve Area in Patients with Acquired Aortic Stenosis. <i>Biomedicines</i> , 2021, 9, 23.	3.2	1
120	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. <i>Blood</i> , 2018, 132, 2004-2004.	1.4	1
121	MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs. <i>Blood</i> , 2018, 132, 1980-1980.	1.4	1
122	Autologous stem cell transplantation in the treatment of multiple myeloma patients with 17p deletion. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 106-111.	0.4	1
123	Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia. <i>Blood</i> , 2021, 138, 546-546.	1.4	1
124	ChÅoniak Hodgkina u osÅ ^{3b} w wieku podeszÅym. <i>Acta Haematologica Polonica</i> , 2013, 44, 156-160.	0.3	0
125	Dwu-, trzy- i czterolekowe schematy w leczeniu pierwszoliniowym szpiczaka plazmocykowego z uwzglÅ [™] dnieniem efektÅ ^{3w} terapii z zastosowaniem bortezomibu. <i>Acta Haematologica Polonica</i> , 2014, 45, 26-34.	0.3	0
126	Nietypowe objawy kliniczne szpiczaka plazmocykowego. <i>Acta Haematologica Polonica</i> , 2017, 48, 189-194.	0.3	0

#	ARTICLE	IF	CITATIONS
127	Quiz What is your diagnosis?. Polish Journal of Pathology, 2018, 69, 107-107.	0.3	0
128	P0712TRANSGELIN AS A POTENTIAL MARKER OF RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
129	P0745URINE TIMP-2 AND IGFBP-7- NEW BIOMARKERS OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
130	MO128RETINOL BINDING PROTEIN (RBP) - NEW BIOMARKER OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
131	C-met Receptor as a Potential Target for the Treatment of Patients with Multiple Myeloma.. Blood, 2005, 106, 3395-3395.	1.4	0
132	Comparison of Myeloma Cells Killing Efficiency by Geldanamycin and Its Analogs.. Blood, 2006, 108, 5027-5027.	1.4	0
133	Increased Expression of Pro-Angiogenic and Decreased Expression of Osteogenic Genes by Multipotential Stromal Cells after Stimulation with Myeloma-Derived Microvesicles.. Blood, 2007, 110, 3515-3515.	1.4	0
134	Ultrafiltration rate and diabetes as useful indicators of cardiovascular-related death in hemodialysis patients below 60 years of age. Postepy Higieny I Medycyny Doswiadczalnej, 2017, 71, 0-0.	0.1	0
135	The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients. Blood, 2018, 132, 5600-5600.	1.4	0
136	Wyzwania wczesnej diagnostyki szpiczaka plazmocytoowego â€“ algorytm diagnostyczny. Acta Haematologica Polonica, 2019, 50, 121-129.	0.3	0
137	Next-generation immunomodulatory drugs in multiple myeloma. Postepy Higieny I Medycyny Doswiadczalnej, 2019, 73, 791-802.	0.1	0
138	Monoclonal gammopathies of undetermined significance and smoldering myeloma. Acta Haematologica Polonica, 2020, 51, 193-202.	0.3	0
139	Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes. Blood, 2021, 138, 2695-2695.	1.4	0
140	Professor Tadeusz Tempka (1885â€“1974). Polish Archives of Internal Medicine, 2020, 130, 924-925.	0.4	0
141	Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group. Blood, 2020, 136, 36-37.	1.4	0